Product Description
NRL-1049 is a product candidate from Neurelis for the treatment of cerebral cavernous malformations (CCMs). (Sourced from: https://neurelis.com/our-pipeline/nrl-1049)
Mechanisms of Action: ROCK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Neurelis
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Central Nervous System Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|